Sign In
Search Icon
Menu Icon

COVID​-19 The​​rapeutic​s

Updated Guidelines Regarding Allocation of Bamlanivimab​/
Et​​esevimab and REGEN-CO​V​​​ Therapeutics

States and Territories can​​ continue to o​​rder both products

Learn More

COVID-19 therapeutics can be used to prevent or treat eligible non-hospitalized patients who have tested positive for COVID-19 and have mild to moderate symptoms. Prevention and early treatment for eligible patients can help improve patient outcomes, reduce stress on healthcare facilities, and even save lives.

HHS/ASPR has purchased supplies of COVID-19 therapeutic products and we are working with state and territorial health departments as well as national healthcare and medical organizations and associations to get the treatments into the hands of healthcare providers quickly, with a focus on areas of the country hardest hit by the pandemic.​​

Featured Resources

​Products Purchased by the US Government

Oral Antiviral: Molnupiravir - Emergency Use Authorization 
Oral Antiviral: Paxlovid - Emergency Use Authorization  
Monoclonal Antibody: Evusheld - Emergency Use Authorization 
Monoclonal Antibody: Sotrovimab - Emergency Use Authorization  
Monoclonal Antibody: REGEN-COV - Emergency Use Authorization 
Monoclonal Antibody: Bamlanivimab/Etesevimab - Emergency Use Authorization  
Monoclonal Antibody: Bamlanivimab - Emergency Use Authorization Revoked​ 

​Resources for Professionals

Healthcare Providers
and COVID-19 Patients

Visit Combat COVID to find out what patients and providers need to know ab​out treatment options for COVID-19.

Visit Combat COVID​​







​​​
​​